iRhythm Technologies (NASDAQ:IRTC) Sees Unusually-High Trading Volume Following Strong Earnings

Key Points

• iRhythm beat quarterly expectations: The company reported EPS of $0.58 versus analysts’ expected $0.04 loss, while revenue rose 20.1% year over year to $224.17 million, exceeding estimates. Shares gained about 1.8% amid elevated trading volume.
• VitalConnect acquisition could expand growth: iRhythm agreed to acquire VitalConnect for $287.5 million, adding monitoring capabilities across hospital and ambulatory settings. Management expects the deal to close by year-end.
• Outlook is positive but risks remain: The company projected 2026 revenue of $880 million to $890 million and a 13%–14% adjusted EBITDA margin, while analysts maintain a “Moderate Buy” consensus. However, iRhythm remains unprofitable on a net-margin and return-on-equity basis, and acquisition integration could pressure execution.

Shares of iRhythm Technologies (NASDAQ:IRTC - Get Free Report) saw an uptick in trading volume on Friday after the company announced better than expected quarterly earnings. Approximately 528,408 shares traded hands during trading, a decline of 13% from the previous session's volume of 604,272 shares.The stock last traded at $130.9950 and had previously closed at $128.12.

The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.62. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.The firm had revenue of $224.17 million during the quarter, compared to analyst estimates of $219.30 million. During the same period last year, the company earned ($0.32) EPS. iRhythm Technologies's quarterly revenue was up 20.1% compared to the same quarter last year.

Key Stories Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q2 results beat expectations: iRhythm reported earnings of $0.58 per share versus the consensus estimate of a $0.04 loss, while revenue rose 20.1% year over year to $224.17 million, exceeding estimates of $219.30 million. The improvement compares with a $0.32-per-share loss in the prior-year quarter. iRhythm Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: VitalConnect acquisition expands the platform: iRhythm agreed to acquire VitalConnect for $287.5 million, adding monitoring capabilities across ambulatory, inpatient and hospital-to-home care. Management expects the transaction to close by year-end, potentially expanding its addressable market and product portfolio. iRhythm to Buy VitalConnect for $287.5M
• Positive Sentiment: Full-year outlook remains solid: iRhythm forecast 2026 revenue of $880 million to $890 million, broadly in line with the roughly $881.3 million analyst consensus, and targeted a 13% to 14% adjusted EBITDA margin. The guidance reinforces expectations for continued growth and improving operating leverage. iRhythm Outlines 2026 Revenue Outlook
• Neutral Sentiment: Legal overhang addressed: A proposed class-action settlement for purchasers of iRhythm common stock received court approval, potentially reducing litigation uncertainty, although the announcement did not specify the settlement’s financial impact. Proposed iRhythm Class Action Settlement
• Negative Sentiment: Profitability and execution remain concerns: Despite the quarterly EPS surprise, iRhythm still reported a negative net margin and negative return on equity. Investors will also monitor the cost, integration and execution risks associated with the VitalConnect transaction.

Analyst Ratings Changes

IRTC has been the subject of a number of recent analyst reports. Bank of America lowered their target price on shares of iRhythm Technologies from $225.00 to $180.00 and set a "buy" rating for the company in a research note on Monday, May 18th. Stephens assumed coverage on shares of iRhythm Technologies in a report on Thursday, July 23rd. They set an "overweight" rating and a $160.00 price objective for the company. Canaccord Genuity Group lowered their price objective on shares of iRhythm Technologies from $180.00 to $152.00 and set a "buy" rating for the company in a research report on Monday, June 1st. Needham & Company LLC dropped their target price on shares of iRhythm Technologies from $255.00 to $192.00 and set a "buy" rating on the stock in a research note on Friday. Finally, Wells Fargo & Company reduced their target price on shares of iRhythm Technologies from $200.00 to $180.00 and set an "overweight" rating on the stock in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $180.21.

Insiders Place Their Bets

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar bought 5,312 shares of the business's stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $10.71 per share, with a total value of $56,891.52. Following the transaction, the director owned 25,611 shares of the company's stock, valued at approximately $274,293.81. This trade represents a 26.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On iRhythm Technologies

Institutional investors have recently bought and sold shares of the business. Hussman Strategic Advisors Inc. purchased a new position in iRhythm Technologies during the 4th quarter worth $2,608,000. UBS Group AG boosted its holdings in iRhythm Technologies by 190.3% in the fourth quarter. UBS Group AG now owns 153,218 shares of the company's stock worth $27,187,000 after acquiring an additional 100,435 shares in the last quarter. Rock Springs Capital Management LP boosted its holdings in iRhythm Technologies by 11.4% in the first quarter. Rock Springs Capital Management LP now owns 261,750 shares of the company's stock worth $30,892,000 after acquiring an additional 26,750 shares in the last quarter. M&T Bank Corp purchased a new stake in shares of iRhythm Technologies during the fourth quarter worth about $3,933,000. Finally, Legal & General Group Plc grew its stake in shares of iRhythm Technologies by 24.0% during the fourth quarter. Legal & General Group Plc now owns 52,070 shares of the company's stock worth $9,239,000 after acquiring an additional 10,065 shares during the last quarter.

iRhythm Technologies Trading Up 1.8%

The company has a debt-to-equity ratio of 4.03, a current ratio of 5.17 and a quick ratio of 4.98. The stock has a market cap of $4.28 billion, a price-to-earnings ratio of -152.96 and a beta of 1.30. The company's fifty day moving average price is $114.76 and its 200-day moving average price is $124.55.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source